Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.1K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.1K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.2K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

2.0K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.0K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.9K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.9K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.5K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Psychological and Behavioural Correlates of Workplace Victimization.

Brain sciences·2026
Same author

The early history of the ESID registry.

Journal of human immunity·2026
Same author

The Muscle Function Deficit Concept and Inflammaging.

Biomedicines·2026
Same author

A new tool for assessing tobacco use among health profession students: an updated version of the Global Health Professions Student Survey (GHPSS).

La Clinica terapeutica·2026
Same author

The skeletal muscle function deficit: From an operational definition to clinic results from the InCHIANTI longitudinal study.

Experimental gerontology·2026
Same author

Digital Innovation in Asthma Management in Italy: Results From the "Confronting Asthma Survey".

Clinical and translational allergy·2025

Related Experiment Video

Updated: Mar 19, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.6K

Fluticasone/formoterol association favors long-lasting decrease in bronchial reactivity to methacholine and weekly

Sara Cortese1, Alessia Gatta1, Loredana Della Valle1

  • 1Department of Medicine and Science of Aging, G. d'Annunzio University, Chieti, Italy.

International Journal of Immunopathology and Pharmacology
|June 9, 2016
PubMed
Summary

Inhaled corticosteroids/long-acting beta-agonists combination therapy improved asthma control by reducing bronchial hyperreactivity and peak expiratory flow variability. The fluticasone/formoterol combination showed superior effects compared to higher steroid doses with as-needed short-acting beta-agonists.

Keywords:
bronchial hyperreactivityfluticasone/formoterol associationmethacholinepeak expiratory flow (PEF) variability

More Related Videos

Employing the Forced Oscillation Technique for the Assessment of Respiratory Mechanics in Adults
06:11

Employing the Forced Oscillation Technique for the Assessment of Respiratory Mechanics in Adults

Published on: February 9, 2022

6.5K
Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography
08:58

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography

Published on: July 10, 2018

44.2K

Related Experiment Videos

Last Updated: Mar 19, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.6K
Employing the Forced Oscillation Technique for the Assessment of Respiratory Mechanics in Adults
06:11

Employing the Forced Oscillation Technique for the Assessment of Respiratory Mechanics in Adults

Published on: February 9, 2022

6.5K
Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography
08:58

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography

Published on: July 10, 2018

44.2K

Area of Science:

  • Pulmonology
  • Pharmacology
  • Clinical Medicine

Background:

  • Inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) are cornerstone asthma therapies.
  • Assessing the impact of ICS/LABA combinations on bronchial hyperreactivity (BHR) and peak expiratory flow (PEF) variability is crucial for optimizing asthma management.
  • These parameters correlate with asthma morbidity and exacerbation risk.

Purpose of the Study:

  • To evaluate the effect of a fixed-dose ICS/LABA combination versus ICS with as-needed LABA on BHR and PEF variability in mild persistent asthma.
  • To compare different dosing strategies of fluticasone and formoterol in managing asthma control markers.

Main Methods:

  • Thirty-six adult patients with mild persistent asthma were randomized into three groups for 6 weeks.
  • Group 1 received fluticasone 125 μg + formoterol 5 μg daily.
  • Groups 2 and 3 received fluticasone 125 μg + formoterol 12 μg or fluticasone 250 μg + formoterol 12 μg as needed, respectively.
  • Weekly PEF variability and methacholine PD20 (PD20 MCH) were assessed.

Main Results:

  • All groups showed decreased weekly PEF variability, with the greatest reduction in the fixed-dose ICS/LABA group (Group 1).
  • Post-treatment PD20 MCH significantly increased across all groups, with the most substantial increase observed in Group 1, followed by Group 3, then Group 2.
  • The fixed-dose fluticasone/formoterol association demonstrated superior improvements in both BHR and PEF variability.

Conclusions:

  • ICS/LABA combination therapy significantly improves BHR and PEF variability in mild persistent asthma.
  • The fixed-dose fluticasone/formoterol combination therapy is more effective than higher doses of ICS with as-needed LABA.
  • Optimizing ICS/LABA therapy, particularly with fixed-dose combinations, can lead to better asthma control and potentially reduce exacerbations.